Testing a virus-based treatment for T-cell lymphoma

Plain-English translation of NCT06508463 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a new treatment called VSV-hIFNβ-NIS, which is a virus that has been genetically engineered to fight cancer. The medication is given as an intravenous infusion (through a vein) along with , an immunotherapy drug that helps your immune system recognize and attack cancer cells. Researchers want to see if this combination, with or without an additional medicine called , can help people with peripheral T-cell lymphoma that has returned or stopped responding to other treatments.

Peripheral T-cell lymphomas are aggressive blood cancers that are difficult to treat, and many patients relapse or don't respond well to standard therapies. This trial exists because researchers believe that using an engineered virus to directly attack cancer cells, combined with drugs that boost the immune system, might offer a new and more effective treatment option.

Do you qualify?

You likely qualify if…

you are 18 years old or older
you have been diagnosed with peripheral T-cell lymphoma (including specific subtypes like mycosis fungoides or anaplastic large cell lymphoma) that has relapsed or stopped responding to previous treatment
your liver and kidney function are relatively normal based on recent blood tests
you have adequate blood cell counts (neutrophils, platelets, and hemoglobin)
you have measurable disease visible on imaging scans or detectable cancer cells in your blood
you are able to travel to Mayo Clinic for visits and follow-up appointments

You likely don't qualify if…

you have a curative treatment option available that you are willing to pursue
you have an active, uncontrolled infection or active tuberculosis or hepatitis
you have received recent chemotherapy (within 2 weeks) or immunotherapy (within 4 weeks)
you have serious heart disease, known coronary artery disease, or certain heart rhythm problems
you have active cancer involvement in your central nervous system or an active seizure disorder

What participation looks like

You would receive the experimental medication through an IV infusion on day 1 after an initial dose of on day -3 (three days before). You may also take by mouth for a few days after treatment to manage symptoms. Throughout the study, you'll undergo imaging scans (CT, PET, and SPECT scans) and blood work to monitor how you respond. After treatment ends, you'll have follow-up visits every 3 months for the first year, then every 6 months for another year, plus a 28-day check-in immediately after treatment.

AI-generated summary from trial data · Jul 3, 2026 · Not medical advice

Testing a virus-based treatment for T-cell lymphoma

What is this trial?

Do you qualify?

What participation looks like

Trial locations